That's just for now....if Biden's health wanes over the next year, then Kamala Harris will be president and we can all welcome socialism then.
Joe Biden - The Fake President
- Thread starter TreeFrogTrader
- Start date
I think the next 4 years will be as entertaining as the past 4 with all this back and forth haha...
Ordering Costco popcorn supplies..
Ordering Costco popcorn supplies..
Oh, for real? Like Kamala is going to nationalize corporations or what? Is it like paying workers overtime and universal healthcare?
Why will it be necessary to involve the military in the logistics? Is the military involved in the logistics of flu vaccines to CVS, Walgreens, Walmart, doctors, etc? Are there major issues annually with the logistics of any vaccines historically in the United States?
The US already has 1000s vaccine centers all across the US. They are called pharmacies and doctor offices. Do you not have a CVS, Walgreens, Walmart, etc. near you?
Please explain how the existing logistics infrastructure is lacking and will be the cause of major logistical issues that requires the military to be involved in the logistics and distribution?
Last edited:
This was one of the great achievements of Donald Trump, Mike Pence and Operation Warp Speed. He had the incredible foresight to get the distribution and production channels amped up and ready to go while the vaccines were being developed. This is why the distribution of the vaccine will be able to be started so quickly. After the military does the initial distributions, then places like Walgreens etc will begin doing vaccinations starting in Feb or March of 2021. Operation Warp Speed was also the driving force in building and converting factories to ramp up output.
The U.S. Military is one of the best and most capable logistics entities in the world. The number of doses of cold storage vaccine that must be delivered in the minimal amount of time is one of the largest logistic challenges in history. CVS, Walgreens, etc. do not have the cold storage logistics capability needed to handle it.
The U.S. government is relying completely on the private sector to transport and cold-store the COVID vaccine. Only one company, McKesson, has agreed to distribute the vaccine. The company does not have anywhere near the necessary logistics and resources needed to distribute and cold store hundreds of millions of COVID vaccine doses over a few months.
Other large countries (e.g. Germany) have their militarizes involved in the vaccine distribution -- allowing them to vaccinate their entire populations by the end of April (if the vaccine doses are delivered on schedule).
For more info...
https://www.elitetrader.com/et/threads/latest-vaccine-news.343809/page-32
Maybe follow the news when Pfizer talked about the storage logistical issues with respect to its vaccine...
Why Pfizer’s ultra-cold COVID-19 vaccine will not be at the local pharmacy any time soon
But the vaccine’s complex and super-cold storage requirements are an obstacle for even the most sophisticated hospitals in the United States and may impact when and where it is available in rural areas or poor countries where resources are tight.
The main issue is that the vaccine, which is based on a novel technology that uses synthetic mRNA to activate the immune system against the virus, needs to be kept at minus 70 degrees Celsius (-94 F) or below.
“The cold chain is going to be one of the most challenging aspects of delivery of this vaccination,” said Amesh Adalja, senior scholar at Johns Hopkins Center for Health Security.
As a follow-up regarding testing the COVID-19 vaccine on the elderly.
Moderna’s COVID-19 Vaccine’s Biggest Breakthrough Is How It Works for the Elderly
https://observer.com/2020/11/moderna-covid-vaccine-effective-age-gender-ethnic-groups/
Moderna’s and Pfizer’s successful COVID-19 vaccines are not only 95 percent effective in preventing the coronavirus, but their final trial results have also revealed that they work equally well across age groups, ethnicities and genders.
On Monday morning, Moderna announced that its vaccine showed excellent results among high-risk groups, such as the elderly and those with underlying conditions. More than 7,000 participants in Moderna’s 30,000-person efficacy trial and Pfizer’s 45,000-person trial were over age 65; about 5,000 were under 65 but had pre-existing conditions or existing diseases that put them at a higher risk of severe COVID-19. Moderna’s final trial results were released on Monday and Pfizer’s results released on November 18.
Efficacy data were also consistent across ethnic groups. More than 11,000 participants in the two trials were from communities of color.
Even better, Moderna said Monday that its mRNA-1273 vaccine is 100 percent effective against severe COVID-19 cases. No one in the company’s efficacy trial who received two doses of the vaccine developed severe COVID-19 symptoms, while 30 people in the placebo group did.
Considering the vaccine’s rarely high efficacy rate, Moderna’s CEO Stéphane Bancel recommended it be given to high-risk groups only, given the fact that the initial supply is limited.
“Give it to health care workers, give it to the elderly, give it to people with diabetes, overweight, heart disease. A 25-year-old healthy man? Give him another vaccine,” Bancel was quoted as saying by Science magazine.
The U.S. government has pre-ordered 100 million doses from Moderna and Pfizer each. But Moderna says it’s only capable of producing about 20 million doses by the end of the year. Pfizer will have about 50 million doses ready, but they will be split between the U.S. and other countries with which the company has purchase agreements.
Pfizer filed the emergency use authorization (EUA) application for its vaccine with the FDA last week. Moderna plans to submit its application on Monday. The Boston startup said it was told that the FDA would convene on December 17 to review its EUA application and could issue the authorization as early as December 20.